| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
Phase 2 Readout example | RPT-904 food allergy | Phase 2b | — | Small Molecules | Digestive System | ||
Phase 2 Readout example | RPT-904 food allergy | Phase 2b | — | Small Molecules | Digestive System | ||
Phase 2 Readout example | RPT-904 food allergy | Phase 2b | — | Small Molecules | Digestive System |
Recent Updates
Recently added Catalysts
RAPT Therapeutics, Inc.$58.02
+0.04 (+0.07%)
D 34Pipeline Score Richly Valued Pharma · Clinical
Market Cap
1.61 B
EPS
-11.07
P/E Ratio
-
Value Trade
645.21 M
SEC Financials
Q3 2025Dilution Risk
R&D Expenses
12.03 M
Total Assets
165.74 M
Total Liabilities
13.76 M
Equity
151.98 M
D/E Ratio
12,345
0.21 %
Week
0.66 %
1 Month
84.07 %
3 Month
391.28 %
6 Month
-62.75 %
5 Year
-40.8 %
All Time
Cash Data
Cash Position
157.34 M
Monthly Burn
6.46 M
Runway
20.1 mo
Burn Trend
StableSEC Filing
Nov 6, 2025
Overview
Volume
11.13 M
52 Week Range
5.67 - 58.02
% held by Insiders
48.8 %
% held by Institutions
66.35 %
Enterprise Value
1.45 B
Total Shares
16.51 M
Short %
22.48 %
Float Shares
5.96 M
Company Description
locked
Upcoming Catalyst
Drug Pipeline Intelligence
D34
Pipeline Score $188M
Pipeline ValueRichly Valued
Valuation Signal4
Drugs Scored0.1x
rNPV / MCap Top 44%
Micro Cap (rank 508 of 905)
Percentile RankRAPT Therapeutics, Inc. faces pipeline headwinds (34/100), with $576M risk-adjusted pipeline value, led by RPT193 in Atopic Dermatitis (Phase 1).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| RPT193 Small molecule | Atopic Dermatitis | Phase 1 | NCT04271514 | 10% | $293M | COMPLETED | 103 | - | - | Apr 26, 2021 | - | Sep 30, 2021 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
RPT904 | chronic spontaneous urticaria | Phase 2 | 2025-10-21 | |||
RPT904 | chronic spontaneous urticaria | Phase 2 | 2025-10-21 | |||
RPT904 | chronic spontaneous urticaria | Phase 2 | 2025-10-21 |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in RAPT
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
RAPT Therapeutics, Inc. (RAPT) Analyst Ratings & Price Targets
Symbol
Firm
Rating
Action
Price Target
Upside
date
RAPT
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
RAPT
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
RAPT
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
RAPT Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
RAPT Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
Competitive Position
How RAPT ranks across every disease it competes inCompetitive Position is a premium feature
See how RAPT ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial